Masciangelo R

No ORCID on file · 3 papers in corpus
2026
Clinical use of recombinant human luteinizing hormone beyond hypogonadotropic hypogonadism: a multicenter descriptive analysis from five Italian fertility centers.
Reproductive biology and endocrinology : RB&E ·doi:10.1186/s12958-026-01551-y

BackgroundRecombinant human luteinizing hormone (rLH) was originally introduced to supplement recombinant human follicle-stimulating hormone (rFSH) for controlled ovarian stimulation (COS) in patients with hypogonadotropic hypogonadism. Pro…

2024
To Assess or Not to Assess: Reconsidering Day 3 Embryo Quality in Planned Freeze-All Blastocyst Cycles.
Journal of personalized medicine ·doi:10.3390/jpm14060624

Day 3 embryo quality is a predictor of in vitro fertilization (IVF) success rates in cleavage-stage embryo transfer. However, the association between day 3 embryo quality and clinical outcomes in blastocyst transfer policy is largely unknow…

other 2018
Safety of ovarian tissue transplantation in patients with borderline ovarian tumors
Human Reproduction ·doi:10.1093/humrep/dex352

STUDY QUESTION: Is transplantation of cryopreserved ovarian tissue from patients with borderline ovarian tumors (BOTs) a safe procedure? SUMMARY ANSWER: BOT cells were found in frozen-thawed and xenografted ovarian tissue in 1 of 11 BOT pa…